

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Core application of: Sundelin, Johan, et al.  
 Application No.: 10/643,627 Group No.: 1646  
 Filed: August 19, 2003 Examiner: Not yet assigned  
 For: RECOMBINANT C140 RECEPTOR ITS AGONISTS AND ANTAGONISTS,  
 AND NUCLEIC ACIDS ENCODING THE RECEPTOR

Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

SECOND PRELIMINARY AMENDMENT TRANSMITTAL

1. Transmitted herewith for this application are:
  - a. This Second Preliminary Amendment Transmittal (2 pages);
  - b. Second Preliminary Amendment (3 pages); and
  - c. Copy of Notice of Omitted Item(s) in a Nonprovisional Application dated January 30, 2004 (2 pages).

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: 16 March 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MP193-006CP1DV1ACN1DV1M

**FEE DEFICIENCY**

3. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

4. Correspondence Address

Direct all future correspondence to:

Customer Number 30405  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

16 March 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat  
Tracy M. Sioussat  
Registration No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-374-7679  
Facsimile - 617-551-8820



Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Sundelin, Johan, et al

Application No.: 10/643.627

Group No.: 1646

Filed: August 19, 2003

Examiner: not yet assigned

For: RECOMBINANT C140 RECEPTOR ITS AGONISTS AND ANTAGONISTS,  
AND NUCLEIC ACIDS ENCODING THE RECEPTOR

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SECOND PRELIMINARY AMENDMENT**

Dear Sir:

Please amend the above-identified application as follows:

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: 16 March 2004

Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.